Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan

[1]  P. Bruzzi,et al.  Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial , 2016, Supportive Care in Cancer.

[2]  E. Winer,et al.  Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors , 2015, Breast Cancer Research and Treatment.

[3]  S. Barni,et al.  Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.

[4]  N. Masuda,et al.  Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial , 2015, Supportive Care in Cancer.

[5]  Mats O. Karlsson,et al.  Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling , 2014, Pharmaceutical Research.

[6]  M. Kris,et al.  Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy , 2011, Supportive Care in Cancer.

[7]  N. Saijo,et al.  A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. , 2009, Japanese journal of clinical oncology.

[8]  E. Winer,et al.  Lymphopenia associated with adjuvant anthracycline/ taxane regimens. , 2008, Clinical breast cancer.

[9]  L. Mileshkin,et al.  An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital , 2005, British Journal of Cancer.

[10]  M. Piccart,et al.  A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  F. Holmes,et al.  Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.